Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy

BACKGROUND: Treatment options are limited for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after treatment failure with EGFR tyrosine kinase inhibitors (TKIs). This multicenter open-label, phase II study aims to evaluate the efficacy and safety of tislelizumab p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Hua, Zhang, Xueyan, Tian, Panwen, Chu, Tianqing, Guo, Qisen, Yu, Xinmin, Yu, Zhuang, Li, Yalun, Chen, Lijuan, Liu, Jie, Zhang, Yan, Guan, Yan, Shi, Xun, Wang, Jing, Zhao, Yanqiu, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441075/
https://www.ncbi.nlm.nih.gov/pubmed/37597849
http://dx.doi.org/10.1136/jitc-2023-006887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441075/
https://www.ncbi.nlm.nih.gov/pubmed/37597849
http://dx.doi.org/10.1136/jitc-2023-006887

Ejemplares similares